A Study of the Recurrence of Hepatitis C Virus After Achieving a Sustained Virological Response

Background: Hepatitis C virus (HCV) infection continues to be a major public health concern. The advancement of direct-acting antivirals (DAAs) has transformed HCV therapy, making viral elimination possible. Nonetheless, experiencing a relapse following treatment continues to be a difficulty. Objectives: This research intended to evaluate the rate of HCV relapse 84 months after finishing DAA treatment. Methods: The study included 89 patients who had finished DAA therapy and achieved a sustained virologic response (SVR). These patients were monitored for as long as 84 months, with yearly follow-up appointments. Serological assessments for HIV and hepatitis B surface antigen (HBsAg) and HCV-RTPCR were performed. The average age of the participants was 23 years (± 7 years). Results: Among the 89 patients, 41 (46.07%) exhibited genotype 1 (G1), 7 (7.87%) displayed genotype 3 (G3), and 41 (46.07%) represented genotype 4 (G4). The group was made up of 52 males (58.43%) and 37 females (41.57%). A co-morbid condition, thalassemia, was observed in 10 (11.24%). No patients showed positive results for HIV or hepatitis B. During the 84-month follow-up, no relapses or reinfections were noted. Conclusions: The research validates the effectiveness of DAAs in attaining a sustained virologic response and preventing HCV recurrence. Additional research involving larger groups and extended follow-up times is necessary to confirm these results.